238 related articles for article (PubMed ID: 31328873)
1. Daily dietary phosphorus intake variability and hemodialysis patient adherence to phosphate binder therapy.
Tao X; Zhang H; Yang Y; Zhang C; Wang M
Hemodial Int; 2019 Oct; 23(4):458-465. PubMed ID: 31328873
[TBL] [Abstract][Full Text] [Related]
2. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
3. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
[TBL] [Abstract][Full Text] [Related]
4. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants.
Van Camp YP; Vrijens B; Abraham I; Van Rompaey B; Elseviers MM
J Nephrol; 2014 Dec; 27(6):673-9. PubMed ID: 24563270
[TBL] [Abstract][Full Text] [Related]
5. Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders.
Sherman RA
Am J Kidney Dis; 2016 Feb; 67(2):182-6. PubMed ID: 26508681
[TBL] [Abstract][Full Text] [Related]
6. Phosphorus Counting Table for the control of serum phosphorus levels without phosphate binders in hemodialysis patients.
Bertonsello-Catto VR; Lucca LJ; da Costa JAC
Clin Nutr ESPEN; 2019 Aug; 32():153-157. PubMed ID: 31221281
[TBL] [Abstract][Full Text] [Related]
7. Adherence to phosphate binder therapy is the primary determinant of hyperphosphatemia incidence in patients receiving peritoneal dialysis.
Hung KY; Liao SC; Chen TH; Chao MC; Chen JB
Ther Apher Dial; 2013 Feb; 17(1):72-7. PubMed ID: 23379497
[TBL] [Abstract][Full Text] [Related]
8. Dietary habits and counseling focused on phosphate intake in hemodialysis patients with hyperphosphatemia.
Cupisti A; D'Alessandro C; Baldi R; Barsotti G
J Ren Nutr; 2004 Oct; 14(4):220-5. PubMed ID: 15483782
[TBL] [Abstract][Full Text] [Related]
9. Interventional study to improve adherence to phosphate binder treatment in dialysis patients.
Hjemås BJ; Bøvre K; Mathiesen L; Lindstrøm JC; Bjerknes K
BMC Nephrol; 2019 May; 20(1):178. PubMed ID: 31101020
[TBL] [Abstract][Full Text] [Related]
10. Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial.
Yin J; Yin J; Lian R; Li P; Zheng J
BMC Nephrol; 2021 Jul; 22(1):243. PubMed ID: 34210293
[TBL] [Abstract][Full Text] [Related]
11. Multidisciplinary education approach to optimize phosphate control among hemodialysis patients.
Chan MW; Cheah HM; Mohd Padzil MB
Int J Clin Pharm; 2019 Oct; 41(5):1282-1289. PubMed ID: 31302884
[TBL] [Abstract][Full Text] [Related]
12. One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis.
Kendrick J; Parameswaran V; Ficociello LH; Ofsthun NJ; Davis S; Mullon C; Kossmann RJ; Kalantar-Zadeh K
J Ren Nutr; 2019 Sep; 29(5):428-437. PubMed ID: 30679076
[TBL] [Abstract][Full Text] [Related]
13. The adequacy of phosphorus binder prescriptions among American hemodialysis patients.
Huml AM; Sullivan CM; Leon JB; Sehgal AR
Ren Fail; 2012; 34(10):1258-63. PubMed ID: 23013171
[TBL] [Abstract][Full Text] [Related]
14. Phosphates in medications: Impact on dialysis patients
.
Sawin DA; Ma L; Stennett A; Ofsthun N; Himmele R; Kossmann RJ; Maddux FW
Clin Nephrol; 2020 Apr; 93(4):163-171. PubMed ID: 32049627
[TBL] [Abstract][Full Text] [Related]
15. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
Coyne DW; Sprague SM; Vervloet M; Ramos R; Kalantar-Zadeh K
J Nephrol; 2022 Apr; 35(3):875-888. PubMed ID: 35138627
[TBL] [Abstract][Full Text] [Related]
16. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
17. Adherence and knowledge about hyperphosphatemia treatment in hemodialysis patients with hyperphosphatemia.
Nerbass FB; Morais JG; dos Santos RG; Krüger TS; Koene TT; da Luz Filho HA
J Bras Nefrol; 2010; 32(2):149-55. PubMed ID: 21103674
[TBL] [Abstract][Full Text] [Related]
18. Phosphate-control adherence in hemodialysis patients: current perspectives.
Umeukeje EM; Mixon AS; Cavanaugh KL
Patient Prefer Adherence; 2018; 12():1175-1191. PubMed ID: 30013329
[TBL] [Abstract][Full Text] [Related]
19. Self-Motivation Is Associated With Phosphorus Control in End-Stage Renal Disease.
Umeukeje EM; Merighi JR; Browne T; Victoroff JN; Umanath K; Lewis JB; Ikizler TA; Wallston KA; Cavanaugh K
J Ren Nutr; 2015 Sep; 25(5):433-9. PubMed ID: 25912398
[TBL] [Abstract][Full Text] [Related]
20. Gut Microbiome-Derived Uremic Toxin Levels in Hemodialysis Patients on Different Phosphate Binder Therapies.
Wang LC; Tapia LM; Tao X; Chao JE; Thwin O; Zhang H; Thijssen S; Kotanko P; Grobe N
Blood Purif; 2022; 51(8):639-648. PubMed ID: 34375976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
